BioCentury
ARTICLE | Strategy

MedImmune's selections

September 19, 2005 7:00 AM UTC

While sometimes dogged by the pro-blems it has faced with its FluMist influenza vaccine, MedImmune Inc. has been busy signing a slew of deals that will help to expand its pipeline of cancer, inflammation and infectious disease candidates. Last week, the company announced plans to acquire B cell antibody specialist Cellective Therapeutics Inc., which will provide another three preclinical cancer and autoimmune antibodies.

"Our focus from 2004 through 2006 will be on developing an enhanced pro-duct profile and on overcoming the marketplace obstacles that negatively impacted the launch this past season," Vice Chairman, President and CEO David Mott said in a March 2004 conference call to address lower than expected sales of the intranasal flu vaccine . Since then, MEDI (Gaithersburg, Md.) has focused on building its existing products and adding monoclonal antibody and biologics capabilities (see "MedImmune Deal Flow"). ...